Showing results (311-320 of 352) with videos related to
Sort By:
Pageof 36
BMC Musculoskeletal Disorders|May 30, 2019
STepped exercise program for patients with knee OsteoArthritis (STEP-KOA): protocol for a randomized controlled trialKelli D Allen, Dennis Bongiorni, Kevin Caves, et al.Annals of Internal Medicine|December 28, 2020
Stepped Exercise Program for Patients With Knee Osteoarthritis : A Randomized Controlled TrialKelli D Allen, Sandra Woolson, Helen M Hoenig, et al.Journal of General Internal Medicine|September 7, 2019
Discharge Information and Support for Patients Discharged from the Emergency Department: Results from a Randomized Controlled TrialSusan N Hastings, Karen M Stechuchak, Cynthia J Coffman, et al.Contemporary Clinical Trials|June 11, 2017
A problem-solving intervention for cardiovascular disease risk reduction in veterans: Protocol for a randomized controlled trialJason A Nieuwsma, Laura O Wray, Corrine I Voils, et al.Journal of Medicinal Chemistry|October 30, 2014
Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitorJaclyn L Henderson, Bethany L Kormos, Matthew M Hayward, et al.JAMA Network Open|October 2, 2025
Implementation of Group Physical Therapy for Knee Osteoarthritis: A Cluster Randomized Clinical TrialKelli D Allen, Sara Webb, Cynthia J Coffman, et al.Nature Medicine|June 3, 2000
Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cellsR Abonour, D A Williams, L Einhorn, et al.Journal of General Internal Medicine|February 26, 2026
Comparing Approaches to Support Implementation of a Hospital Walking Program: Evidence from a Cluster Randomized TrialSusan N Hastings, Karen M Stechuchak, Caitlin B Kappler, et al.Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.BMC Musculoskeletal Disorders|August 25, 2016
Pain coping skills training for African Americans with osteoarthritis (STAART): study protocol of a randomized controlled trialLeah A Schrubbe, Scott G Ravyts, Bernadette C Benas, et al.Pageof 36